Strategic Partnerships Arrivo Bio is actively engaging with industry partners (evidenced by the Lamassu Bio collaboration and clinical trial involvement) which signals opportunities for co-development, licensing, and funded studies with pharma and biotech players seeking rapid advancement in clinical programs.

Clinical Programs With a RABI-767 program moving into clinical discussions and participation at EPC 2026, there is a tangible entry point for CROs, contract manufacturing organizations, and diagnostic collaborators to support trial design, data management, and regulatory readiness.

Funding Readiness Current funding stature indicates readiness for expanded programs or late-stage development partnerships, suggesting potential for strategic investors or pharma alliances seeking scaled development capabilities and risk-sharing financing.

Market Positioning Positioned as a trusted, value-driven partner focusing on drug development decision efficiency, Arrivo Bio can be targeted for enterprise-grade partnerships with mid-to-large biotechs seeking improved pipeline ROI and accelerated timelines.

Digital & Tech Enablement Existing tech stack and online presence present opportunities to offer integrated data platforms, cloud-based collaboration tools, and secure analytics services to support remote trials, data integration, and partner communications.